Company profile: Silence Therapeutics
1.1 - Company Overview
Company description
- Provider of RNA technology and a proprietary genetic medicine platform leveraging RNA interference to target and silence disease-associated genes without altering DNA. Developing siRNA therapies including zerlasiran (SLN360) to reduce high lipoprotein(a) and divesiran (SLN124) targeting TMPRSS6 to manage iron levels and treat polycythemia vera by increasing hepcidin.
Products and services
- Divesiran (SLN124): siRNA-based therapy targeting TMPRSS6 to manage iron levels and treat polycythemia vera by increasing hepcidin
- MRNAi GOLD™ Platform: Proprietary platform uses RNA interference to target and silence disease-associated genes without altering DNA, harnessing natural cellular mechanisms for therapeutic effects
- Zerlasiran (SLN360): In-development therapy reduces high lipoprotein(a) levels using siRNA, addressing a key cardiovascular risk factor through targeted gene silencing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Silence Therapeutics
Azaya Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions focused on developing therapies for cancer and other serious medical conditions; San Antonio-based, acquired by Cytori Therapeutics in February 2017.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Azaya Therapeutics company profile →
BioDiscovery
HQ: United States
Website
- Description: Provider of software and systems for genetic research and genomic analysis, including Saphyr and Stratys for genome-wide detection of structural variants via optical genome mapping; VIA software to interpret OGM, NGS, and microarray data; and the Ionic system using isotachophoresis to isolate, purify, and concentrate DNA/RNA from cells, tissue, and FFPE.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioDiscovery company profile →
Manta Instruments
HQ: United States
Website
- Description: Provider of scientific instruments using breakthrough technology to characterize nanoparticles more effectively than existing products, including improved measurement of nanoparticle concentration. Based in La Jolla, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Manta Instruments company profile →
Nanotech Energy
HQ: United States
Website
- Description: Provider of graphene, graphene oxide, and graphene-based energy storage, including graphene batteries and super batteries offering fast charging, extended range, longer life, non-flammable properties, and increased safety for electric vehicles. Supplies silver nanowires, conductive inks, and conductive adhesives; holds exclusive UCLA-licensed super battery and supercapacitor IP.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanotech Energy company profile →
2C Tech
HQ: United States
Website
- Description: Provider of quantum dot-based nanotechnology for retinal degenerative diseases, delivering photovoltaic stimulation to the retina via intravitreal injection to activate photoreceptors, preserve or enhance vision, and potentially treat Retinitis Pigmentosa and Macular Degeneration, with neuroprotective effects on neuro-retinal cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 2C Tech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Silence Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Silence Therapeutics
2.2 - Growth funds investing in similar companies to Silence Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Silence Therapeutics
4.2 - Public trading comparable groups for Silence Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →